ATE202573T1 - Biologisch abbaubare polyacetal-polymere, herstellung und anwendung - Google Patents

Biologisch abbaubare polyacetal-polymere, herstellung und anwendung

Info

Publication number
ATE202573T1
ATE202573T1 AT96912522T AT96912522T ATE202573T1 AT E202573 T1 ATE202573 T1 AT E202573T1 AT 96912522 T AT96912522 T AT 96912522T AT 96912522 T AT96912522 T AT 96912522T AT E202573 T1 ATE202573 T1 AT E202573T1
Authority
AT
Austria
Prior art keywords
biodegradable biocompatible
polyacetals
biodegradable
production
application
Prior art date
Application number
AT96912522T
Other languages
English (en)
Inventor
Mikhail Papisov
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23671966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE202573(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE202573T1 publication Critical patent/ATE202573T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L59/00—Compositions of polyacetals; Compositions of derivatives of polyacetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1213—Semi-solid forms, gels, hydrogels, ointments, fats and waxes that are solid at room temperature
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G4/00—Condensation polymers of aldehydes or ketones with polyalcohols; Addition polymers of heterocyclic oxygen compounds containing in the ring at least once the grouping —O—C—O—

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
AT96912522T 1995-04-14 1996-04-01 Biologisch abbaubare polyacetal-polymere, herstellung und anwendung ATE202573T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/421,766 US5811510A (en) 1995-04-14 1995-04-14 Biodegradable polyacetal polymers and methods for their formation and use
PCT/US1996/004476 WO1996032419A1 (en) 1995-04-14 1996-04-01 Biodegradable polyacetal polymers and formation and use

Publications (1)

Publication Number Publication Date
ATE202573T1 true ATE202573T1 (de) 2001-07-15

Family

ID=23671966

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96912522T ATE202573T1 (de) 1995-04-14 1996-04-01 Biologisch abbaubare polyacetal-polymere, herstellung und anwendung

Country Status (10)

Country Link
US (3) US5811510A (de)
EP (1) EP0820473B2 (de)
JP (1) JP4187265B2 (de)
AT (1) ATE202573T1 (de)
AU (1) AU5531296A (de)
CA (1) CA2215997C (de)
DE (1) DE69613569T3 (de)
DK (1) DK0820473T4 (de)
GR (1) GR3036696T3 (de)
WO (1) WO1996032419A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
WO1998058258A1 (de) * 1997-06-18 1998-12-23 Elvira Schecklies Formulierung für immunologische reaktionssysteme
AU761784B2 (en) * 1997-12-09 2003-06-12 Biomedical Frontiers, Inc. Modified polysaccharides exhibiting altered biological recognition
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
JP4813712B2 (ja) * 1999-08-09 2011-11-09 ザ ジェネラル ホスピタル コーポレーション 薬物−担体複合体およびその使用方法
WO2002020663A2 (en) * 2000-09-06 2002-03-14 Ap Pharma, Inc. Degradable polyacetal polymers
US6648883B2 (en) 2001-04-26 2003-11-18 Medtronic, Inc. Ablation system and method of use
US7250048B2 (en) 2001-04-26 2007-07-31 Medtronic, Inc. Ablation system and method of use
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
WO2003059988A2 (en) 2002-01-14 2003-07-24 The General Hospital Corporation Biodegradable polyketal polymers and methods for their formation and use
WO2003070823A2 (en) * 2002-02-20 2003-08-28 The General Hospital Corporation Conjugates comprising a biodegradable polymer and uses therefor
AU2003281208A1 (en) * 2002-07-05 2004-01-23 Asahi Kasei Kabushiki Kaisha Resin compatible with body fluid and living tissue
AU2003256613A1 (en) * 2002-07-19 2004-02-09 Amgen Inc. Protein conjugates with a water-soluble biocompatible, biogradable polymer
CA2492803C (en) * 2002-07-19 2013-11-05 The General Hospital Corporation Oxime conjugates and methods for their formation and use
US7045589B2 (en) 2002-11-15 2006-05-16 A.P. Pharma, Inc. Bioerodible poly(ortho esters) from dioxane-based di(ketene acetals), and block copolymers containing them
US6878374B2 (en) * 2003-02-25 2005-04-12 Nitto Denko Corporation Biodegradable polyacetals
US7048925B2 (en) * 2003-08-28 2006-05-23 Nitto Denko Corporation Acid-sensitive polyacetals and methods
AU2004270251B2 (en) * 2003-09-05 2011-03-31 The General Hospital Corporation Polyacetal drug conjugates as release system
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
WO2005032597A1 (en) * 2003-09-29 2005-04-14 Nitto Denko Corporation Biodegradable polyacetals for in vivo polynucleotide delivery
DE102004023117A1 (de) * 2004-05-11 2005-12-08 A. u. K. Müller GmbH & Co KG Elektromagnetventil für flüssige Medien, insbesondere Heißwasser
US7358223B2 (en) * 2004-10-04 2008-04-15 Nitto Denko Corporation Biodegradable cationic polymers
EP1812074B1 (de) * 2004-10-18 2010-12-29 Nitto Denko Corporation Intrazelluläre peptidabgabe
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
MX2007006833A (es) 2004-12-10 2007-10-08 Talima Therapeutics Inc Composiciones y metodos para tratar condiciones de la unidad de una.
US7674452B2 (en) * 2005-03-16 2010-03-09 Nitto Denko Corporation Polymer coating of cells
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するｐｅｇおよびポリシアルリソソーム酵素のコンジュゲート
US20060229585A1 (en) * 2005-04-11 2006-10-12 Minu, L.L.C. Drug delivery to the crystalline lens and other ocular structures
US7722581B2 (en) * 2005-04-11 2010-05-25 Gholam A. Peyman Crystalline lens drug delivery
US7588754B2 (en) * 2005-05-10 2009-09-15 Nitto Denko Corporation Biodegradable polyacetals and methods
US20060263328A1 (en) * 2005-05-19 2006-11-23 Sang Van Hydrophilic polymers with pendant functional groups and method thereof
WO2007098041A1 (en) * 2006-02-17 2007-08-30 Medtronic, Inc. Polyketal polymers, and methods of making and using same
US7700541B2 (en) * 2006-04-06 2010-04-20 Nitto Denko Corporation Biodegradable cationic polymers
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
US20090061515A1 (en) * 2007-08-29 2009-03-05 Michael Eric Benz Methods of inhibiting or suppressing cellular proliferation
BRPI0820229A2 (pt) * 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
US8101706B2 (en) 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
AR074584A1 (es) * 2008-12-10 2011-01-26 Mersana Therapeutics Inc Formulaciones farmaceuticas de conjugados camtotecina-polimero biocompatibles biodegradables
EP3608330B1 (de) 2008-12-16 2022-11-09 Genzyme Corporation Synthetische zwischenprodukte zur verwendung zur herstellung von oligosaccharid-protein-konjugate
JP2012528240A (ja) 2009-05-28 2012-11-12 メルサナ セラピューティックス， インコーポレイテッド 可変速度放出リンカーを含むポリアル−薬物コンジュゲート
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2012129070A2 (en) 2011-03-24 2012-09-27 Unversity Of Florida Research Foundation, Inc. Acetal metathesis polymerization
EP2717916B1 (de) 2011-06-10 2017-03-08 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
WO2014008375A1 (en) * 2012-07-05 2014-01-09 Mersana Therapeutics, Inc. Terminally modified polymers and conjugates thereof
US10226535B2 (en) 2012-12-10 2019-03-12 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
WO2014093394A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
CA2927022C (en) 2013-10-11 2018-08-21 Asana Biosciences, Llc Protein-polymer-drug conjugates
WO2015054659A1 (en) 2013-10-11 2015-04-16 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗ｈｅｒ２表位之單株抗體及其使用之方法
WO2016050210A1 (zh) 2014-10-01 2016-04-07 厦门赛诺邦格生物科技有限公司 一种多官能化聚乙二醇衍生物及其制备方法
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
BR112018068461A2 (pt) 2016-03-15 2019-01-22 Mersana Therapeutics Inc conjugado, composição farmacêutica, métodos para preparação de um conjugado e para alívio de um sintoma de um câncer.
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
TW201834697A (zh) 2017-02-28 2018-10-01 美商梅爾莎納醫療公司 Her2標靶抗體－藥物結合物之組合療法
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
US10772971B2 (en) 2017-06-22 2020-09-15 Mersana Therpeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
EP4380973A2 (de) 2021-08-02 2024-06-12 Yeda Research and Development Co. Ltd. Anti-matrix-metalloproteinase-14-antikörper zur behandlung von krebs

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024073A (en) * 1972-01-08 1977-05-17 Toray Industries, Inc. Hydrogel and production thereof
US4303767A (en) * 1976-12-02 1981-12-01 Basf Wyandotte Corporation Flame retardant antistatic additives and antistatic fibers
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
DE51707T1 (de) * 1980-11-12 1983-04-14 Izu West Hill Ontario Hattori Dextranpolycarboxylierte saeuren, ihre komplexe mit ferrihydroxyd, sie enthaltende arzneimittel und verfahren zu deren herstellung.
JPS59124901A (ja) * 1982-12-29 1984-07-19 Dai Ichi Seiyaku Co Ltd 多糖誘導体
US4549010A (en) * 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
US4863964A (en) * 1985-07-02 1989-09-05 Biomedical Frontiers, Inc. Method for the stabilization of deferoxamine to chelate free ions in physiological fluid
US4713441A (en) * 1986-08-01 1987-12-15 Sandoz Pharmaceuticals Corp. Polyacetal hydrogels formed from divinyl ethers and polyols
US4793986A (en) * 1987-02-25 1988-12-27 Johnson Matthey, Inc. Macromolecular platinum antitumor compounds
JPH01190636A (ja) * 1988-01-22 1989-07-31 Green Cross Corp:The 制癌作用物質複合体
US4975519A (en) * 1989-05-12 1990-12-04 Hoechst Celanese Corporation Novel polyacetal terpolymers of trioxane and alpha, alpha- and alpha, beta-isomers of glycerol formal and functional derivatives thereof
US5202434A (en) * 1991-04-05 1993-04-13 Merck & Co., Inc. 8a-aza-8a-homoerythromycin lactams
EP0581752B1 (de) * 1992-07-15 1998-12-09 The Procter & Gamble Company Builder enthaltende Zusammensetzungen zur Verhinderung der Farbstoffübertragung
US5393737A (en) * 1992-08-20 1995-02-28 Health Research, Inc. Cytotoxic drug conjugates for treatment of neoplastic diseases
US5359071A (en) * 1993-03-12 1994-10-25 Merck & Co., Inc. 15-substituted 4-azasteroids

Also Published As

Publication number Publication date
EP0820473A1 (de) 1998-01-28
US5863990A (en) 1999-01-26
DE69613569D1 (de) 2001-08-02
EP0820473B1 (de) 2001-06-27
JPH11503481A (ja) 1999-03-26
CA2215997A1 (en) 1996-10-17
US5811510A (en) 1998-09-22
CA2215997C (en) 2009-03-24
GR3036696T3 (en) 2001-12-31
AU5531296A (en) 1996-10-30
DE69613569T2 (de) 2002-05-16
US5958398A (en) 1999-09-28
DK0820473T4 (da) 2008-05-13
DE69613569T3 (de) 2008-07-24
JP4187265B2 (ja) 2008-11-26
WO1996032419A1 (en) 1996-10-17
DK0820473T3 (da) 2001-10-22
EP0820473B2 (de) 2008-01-30

Similar Documents

Publication Publication Date Title
DE69613569D1 (de) Biologisch abbaubare polyacetal-polymere, herstellung und anwendung
DE69839251D1 (de) Alpha interferon-polymer konjugate mit erhöhter biologischer wirksamkeit sowie verfahren zu deren herstellung
WO1996032419B1 (en) Biodegradable polyacetal polymers and formation and use
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
BR0012212A (pt) Processo de hidrogenação de 3-hidroxipropanal em 1,3-propanodiol, processo de preparação de 1,3-propanodiol, processo de purificação de uma solução aquosa de 3-hidroxipropanal e composição de 1,3-propanodiol
KR960016882A (ko) 치주염치료를 위한 서방출형 생분해성 제제
DE69529054D1 (de) System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
CA2236262A1 (en) Room temperature sterilant for medical devices
DE60022302D1 (de) Duftabgebende Faser
ATE127339T1 (de) Ein abgeändertes gesponnenes fasersystem und verfahren zur herstellung.
DE69508938D1 (de) Transdermales arzneistoff-abgabesystem
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
ATE433318T1 (de) Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
EP1228771A4 (de) Verwendung löslicher cellulosederivate, die schwer löslich in wasser gemacht wurden und das verfahren zu ihrer herstellung
NO995908D0 (no) Implantater for kontrollert frigivning av farmasöytisk aktive bestanddeler samt fremgangsmåte for fremstilling derav
DE60108255D1 (de) Clarithromycin enthaltende zubereitung mit verlängerter freisetzung
KR940021071A (ko) 생체기능조정물질
HUT77607A (hu) Kemény szövetet stimuláló szer
KR910009241A (ko) 치근막 질환 치료용 서방성 조성물
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
SE9202208D0 (sv) Vaevnadsfoerstaerkning
HUT78031A (hu) Szívótest, különösen pelenkák, intimbetétek, szlipbetétek, továbbá hasonlók részére és eljárás annak előállítására
CO5280202A1 (es) Metodos de tratamiento y metodos de rastreo de farmacos
TR200000890T2 (tr) Topik ilacın üretilmesi için -amino levülozik asidin kullanılması

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0820473

Country of ref document: EP